An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment
Phase of Trial: Phase III
Latest Information Update: 22 Jun 2018
Price : $35 *
At a glance
- Drugs Cat SPIRE (Primary)
- Indications Allergic rhinoconjunctivitis; Perennial allergic rhinitis
- Focus Therapeutic Use
- Sponsors Circassia
- 21 Aug 2017 Status changed from recruiting to completed.
- 29 Jun 2017 This trial has been discontinued in Germany.
- 18 Jun 2017 This trial has been discontinued in Czech Republic.